P

    Processa Pharmaceuticals Inc (PCSA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.05
    -0.01 (-0.49%)

    Market Cap: $5.75M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    38%(8/21)
    Avg Surprise
    -19.58%
    Streak
    1 Q

    Upcoming Estimates

    Mar 31, 2026
    EPS Consensus$N/A
    Revenue Consensus
    $0
    Range$0 - $0
    0 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 26EST
    		-N/A---
    Jun 26
    		$-1.19N/AN/ABeat-60.8%
    Sep 25
    		$-1.75$-2.00+12.50%Beat+93.2%
    Jun 25
    		$-0.25$-0.23-8.70%Miss+99.0%
    Mar 25
    		$-7.50N/A+61.04%Beat+73.0%
    Dec 24
    		$-0.74$-0.92+19.57%Beat+56.5%
    Sep 24
    		$-25.75$-25.00-3.00%Miss+35.6%
    Jun 24
    		$-25.25$-24.50-3.06%Miss+49.5%
    Mar 24
    		$-27.75$-29.50+5.93%Beat-15316.7%
    Dec 23
    		$-1.70$-1.60-6.25%Miss+99.0%
    Sep 23
    		$-40.00$-50.00+20.00%Beat+78.4%
    Jun 23
    		$-50.00$-75.00+33.33%Beat+68.8%
    Mar 23
    		$-0.18$-0.28+35.71%Beat+99.8%
    Dec 22
    		$-175.00$-152.50-14.75%Miss-83233.3%
    Sep 22
    		$-185.00$-167.50-10.45%Miss-94.7%
    Jun 22
    		$-160.00$-95.00-68.42%Miss-60.0%
    Mar 22
    		$-100.00$-106.67+6.25%Beat-42.9%
    Dec 21
    		$-0.21$-0.19-10.53%Miss+87.6%
    Sep 21
    		$-95.00$-92.50-2.70%Miss+4.8%
    Jun 21
    		$-100.00$-70.00-42.86%Miss-76823.1%
    Mar 21
    		$-70.00$-55.00-27.27%Miss-43650.0%
    Dec 20
    		$-1.69$-0.35-382.86%Miss-634.8%
    Sep 20
    		$-99.75$-80.00-24.69%Miss-62243.8%
    Jun 20
    		$-0.13N/AN/ABeat+27.8%
    Mar 20
    		$-0.16N/AN/ABeat+94.1%
    Dec 19
    		$-0.23N/AN/ABeat+89.6%
    Sep 19
    		$-0.16N/AN/ABeat+94.8%
    Jun 19
    		$-0.18N/AN/ABeat+96.1%
    Mar 19
    		$-2.72N/AN/ABeat+37.6%
    Dec 18
    		$-2.21N/AN/ABeat-
    Sep 18
    		$-3.09N/AN/ABeat-
    Jun 18
    		$-4.61N/AN/ABeat-
    Mar 18
    		$-4.35N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.19EV/EBITDA-0.14x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-464.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio0.87xQuick Ratio0.87x
    Trading Statistics
    Beta0.96Avg Volume56.60K
    52-Week High$14.2552-Week Low$1.67

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.12
    SMA 20$2.26
    SMA 50$2.21
    SMA 200$3.10
    EMA 10$2.14
    EMA 20$2.21
    EMA 50$2.28
    EMA 200$3.37

    MACD

    Line: -0.07Signal: -0.04Hist: -0.03

    ADX

    ADX: 12.1+DI: 19.0-DI: 23.7

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down8.0
    PSAR$2.62

    Bollinger Bands

    Upper Band$2.67
    Lower Band$1.85
    %B Position3622%(Upper)
    Band Width0.24

    RSI (14-Day)

    Neutral
    42.3

    Momentum Oscillators

    Stoch %K10.0
    Stoch %D13.6
    Williams %R-92.6
    ROC (10d)-3.8%
    Momentum-0.08
    CCI (20d)-82.6
    MFI (14d)23.7

    Volatility Measures

    ATR (14d)$0.19(9.2%)
    StdDev (20d)0.20
    Hist Vol72.6%(High)

    Volume Flow

    VWAP$2.06
    OBV1.2B
    AD Line408.2B
    CMF (20d)-0.169

    Volume Metrics

    Avg Vol (20d)54.5K
    Vol Ratio0.3x(Low)
    VWMA (20d)$2.30

    Pivot Points

    R3$2.25
    R2$2.19
    R1$2.13
    Pivot Point$2.07
    S1$2.01
    S2$1.95
    S3$1.89

    Advanced Oscillators

    TSI-8.13
    Ultimate Osc38.6
    KST-30.72

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$12.47M$0$0$0$0$0
    Cost of Revenue$0$0$301$0$0$0$301$0$0$0$140$0
    Gross Profit$0$0$-301$0$0$0$-301$0$0$0$-140$0
    Operating Expenses$2.34M$3.33M$3.70M$3.49M$3.95M$2.85M$2.73M$3.42M$3.08M$2.81M$2.47M$2.17M
    R&D$649,877$1.81M$2.11M$1.66M$2.45M$1.59M$1.71M$2.29M$1.73M$1.54M$1.33M$1.15M
    SG&A$1.69M$1.52M$1.59M$1.83M$1.50M$1.26M$1.02M$1.14M$1.35M$1.27M$1.14M$1.02M
    Operating Income$-2,336,138$-3,331,214$-3,701,889$-3,488,843$-3,950,783$-2,846,990$-2,734,731$-3,424,853$-3,082,024$-2,809,598$-2,469,449$-2,167,612
    Interest Income$-2,003$13,859$0$0$8,862$12,585$0$0$0$0$0$85,661
    Interest Expense$929,356$45,965$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-3,265,494$-3,377,179$-3,289,803$-3,488,843$-3,941,921$-2,834,405$-2,616,860$-3,424,853$-3,082,024$-2,726,381$-2,404,931$-2,081,951
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-3,265,494$-3,377,179$-3,358,938$-3,436,573$-3,933,918$-2,834,405$-2,728,708$-3,384,703$-3,010,326$-2,726,381$-2,404,931$-2,081,951
    EBITDA$-3,263,190$-3,390,737$-3,701,588$-3,488,542$-3,950,482$-2,846,689$-2,734,430$-3,424,650$-3,081,885$-2,726,242$-2,469,309$-2,167,530
    EBIT$-3,263,491$-3,391,038$-3,701,889$-3,488,843$-3,950,783$-2,846,990$-2,734,731$-3,424,853$-3,082,024$-2,726,381$-2,469,449$-2,167,612
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PCSA

    News

    Processa Pharmaceuticals (NASDAQ: PCSA) gains new 5.8% owner with no sole control

    Soleus Capital Master Fund, L.P. and related entities, including Guy Levy, have reported a beneficial ownership of 160,943 shares of Processa Pharmaceuticals (PCSA), representing 5.8% of the outstanding common stock. This ownership grants shared voting and dispositive power but no sole control. The filing was made via a Schedule 13G, indicating a passive investment.

    Stock Titan•8/18/26•
    Neutral

    Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting

    Shareholders of Processa Pharmaceuticals (NASDAQ:PCSA) approved several proposals at their 2026 annual meeting, including an amendment to the 2019 Omnibus Incentive Plan to increase shares available for issuance by 200,000. All six directors were re-elected, and Cherry Bekaert, LLP was ratified as the independent accounting firm. An advisory vote on executive compensation also passed, with the meeting establishing a quorum.

    Investing.com•8/15/26•
    Neutral

    Processa Pharmaceuticals 3Q 2026: Net loss $(3.27M), EPS $(1.19) — 10-Q Summary

    Processa Pharmaceuticals (PCSA) reported a net loss of $(3.27M) and diluted EPS of $(1.19) for the third quarter of 2026, showing an improvement from the previous year, with no product revenue. The company recently acquired Vidya, securing $200M in funding to advance new clinical programs targeting conditions like food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis. Processa also streamlined its pipeline by returning PCS6422 to Elion to focus on core assets.

    TradingView•8/15/26•
    Somewhat-Bullish

    Form 8K Processa Pharmaceuticals Inc For: 14 August By Investing.com

    This article reports on the filing of a Form 8K by Processa Pharmaceuticals Inc. on August 14. The 8K filing is a standard SEC disclosure for significant corporate events, but the article does not provide specific details about the content of this particular filing. It highlights the company's stock symbol, PCSA, and its percentage change.

    Investing.com Nigeria•8/14/26•
    Neutral

    Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting

    Processa Pharmaceuticals shareholders approved several key proposals at their 2026 annual meeting on July 30, including an amendment to the 2019 Omnibus Incentive Plan to increase shares available for issuance by 200,000. Additionally, all six directors were re-elected, Cherry Bekaert, LLP was ratified as the independent accounting firm, and an advisory vote on executive compensation was approved. These decisions were made with a quorum of at least one-third of outstanding common stock represented.

    Investing.com•8/14/26•
    Neutral

    Frequently Asked Questions About PCSA

    Does PCSA pay dividends?
    Processa Pharmaceuticals Inc (PCSA) does not currently pay a regular dividend.
    What is PCSA's market cap?
    Processa Pharmaceuticals Inc (PCSA) has a market capitalization of $5.75M with a current stock price of $2.05.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In